3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
20
Breast Neoplasms
10
Fallopian Tube Neoplasms
9
Triple Negative Breast Neoplasms
3
Stomach Neoplasms
3
Lung Neoplasms
3
Colonic Neoplasms
3
Carcinoma, Ovarian Epithelial
3
Uterine Cervical Neoplasms
2
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Hereditary Breast and Ovarian Cancer Syndrome
2
Testicular Neoplasms
1
Stage IV Fallopian Tube Cancer AJCC v6 and v7
1
Renal Insufficiency
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Peritoneal Neoplasms
1
Neoplasms, Unknown Primary
1
Liver Failure
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Hepatocellular
1
Brenner Tumor
1
Breast Neoplasms, Male
1
Interventions
Carboplatin
19
Paclitaxel
17
Cisplatin
9
Cyclophosphamide
8
Gemcitabine
7
Bevacizumab
6
Topotecan
5
pembrolizumab
4
olaparib
4
liposomal doxorubicin
4
durvalumab
4
Letrozole
4
Interleukin-2
4
Drug Therapy
4
Doxorubicin
4
Albumin-Bound Paclitaxel
4
rucaparib
3
fludarabine
3
chiauranib
3
cemiplimab
3
camrelizumab
3
Therapeutics
3
Itraconazole
3
Injections
3
Hyperthermic Intraperitoneal Chemotherapy
3
Everolimus
3
pazopanib
2
iniparib
2
eprenetapopt
2
avelumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
veliparib
×
Gynecologic
×
Clear all
NCT01472783
2016-11-16
Veli-BRCA
Vejle Hospital
Phase 1/2
Completed
49 enrolled